On September 9, 2025, Xilio Therapeutics, Inc. announced the initiation of Phase 2 clinical trials for efarindodekin alfa (XTX301) and the achievement of a $17.5 million milestone with Gilead Sciences. As of June 30, 2025, the company has $121.6 million in cash, enabling operations through Q1 2027.